160 results about "Cytochrome" patented technology

The invention belongs to the field of genetic engineering and synthetic biology, and provides a novel cytochrome P450 enzyme derived from cephalotaxus plants, a nucleotide, a carrier and a host of the cytochrome P450 enzyme, and application of the cytochrome P450 enzyme in preparation of cephalotaxane diterpenoid compounds. The cytochrome P450 enzyme provided by the invention has multiple catalytic functions, can efficiently catalyze oxidation of C-5 site and C-19 site of cephalotaxene, lays a solid foundation for analysis of a cephalotaxane diterpene biosynthetic pathway, and provides a new method for obtaining important active molecules such as cephalotaxus hainanensis lactone and the like by adopting a synthetic biological means.

The invention relates to a group of specific amplification primers for mitochondrial genes of procambarus clarkia and application thereof, and belongs to the technical field of molecular biology, and the mitochondrial genes of the procambarus clarkia comprise cytochrome c oxidase I subunit genes and cytochrome b genes. The specific amplification primer of the CO I gene comprises a CO I gene upstream primer and a CO I gene downstream primer, wherein the base sequences of the CO I gene upstream primer and the CO I gene downstream primer are respectively shown as SEQ NO.1 and SEQ NO.2; the specific amplification primer of the Cytb gene comprises a Cytb gene upstream primer and a Cytb gene downstream primer of which the base sequences are respectively as shown in SEQ NO.3 and SEQ NO.4. The invention further discloses a kit for detecting the Cytb gene. According to the amplification method of the mitochondrial gene of the procambarus clarkia, PCR (Polymerase Chain Reaction) amplification is carried out on a DNA (Deoxyribonucleic Acid) template solution of the procambarus clarkia by adopting amplification primers of a mitochondrial COI gene and a Cytb gene of the procambarus clarkia. The procambarus clarkia mitochondrial gene specific amplification primer has high specificity, a single target gene can be stably amplified, the length of the obtained procambarus clarkia mitochondrial COI gene segment reaches about 1000 bp, and the length of the obtained procambarus clarkia mitochondrial Cytb gene segment reaches about 800 bp.

The invention discloses an application of a tobacco cytochrome protein P450 gene, and particularly relates to an application of the tobacco cytochrome protein P450 gene in regulation and control of tobacco dwarfing, and the tobacco cytochrome protein P450 gene is an NtCYP71AU50 gene and / or an NtCYP78A7 gene; the nucleotide sequence of the NtCYP71AU50 gene is as shown in SEQ ID NO. 1, and the nucleotide sequence of the NtCYP78A7 gene is as shown in SEQ ID NO. 3. According to the invention, an editing vector for knocking out NtCYP71AU50 and NtCYP78A7 genes is constructed by virtue of a CRISPR / Cas9 mediated gene editing technology, NtCYP71AU50 and NtCYP78A7 gene editing plants are obtained after genetic transformation, and the plant height, stem girth, waist leaf length, waist leaf width and leaf area of the two gene editing plants are lower than those in a control group. By regulating and controlling the growth and development process of the tobacco plants, the tobacco plants are promoted to be dwarfed, and the problem of shortage of tobacco dwarfing resources is solved, so that application of the tobacco plants in dwarfing close planting cultivation is promoted, the lodging resistance of the tobacco is enhanced, and possibility is provided for increasing the yield per unit area.

The invention belongs to the technical field of biology, and particularly relates to a construction method and application of a tobacco plant for expressing rare ginsenoside. According to the method, dammarendiol synthase DDS, cytochrome P450 CYP716A47 and glycosyl transferase UGTPg1 / UGTPg45 are added into tobacco, heterologous synthesis of rare ginsenosides CK and Rh2 is achieved, dependence on traditional ginseng cultivation extraction is avoided, and cost is remarkably reduced and efficiency is remarkably improved. The characteristics of short growth cycle and easy culture of tobacco are utilized to overcome the problems of low efficiency and low yield of traditional synthesis; positive transgenic tobacco leaves are dedifferentiated to form callus cells, so that materials are provided for large-scale fermentation, and an industrial production foundation is laid.

The application discloses a kind of generation (4S) 4-hydroxyisophorone monooxygenase mutant and preparation method thereof, the monooxygenase is cytochrome P450 BM3 Monooxygenase from bacillus megaterium. The cytochrome P450 BM3 Monooxygenase mutant has high stereoselectivity and high reaction activity to catalyze isophorone hydroxylation, mutant R47L / Y51F / F81W / A191T / N239H / I259V / A276T / A328I / A330S / L353I / I401L / L437LL catalyzes isophorone to obtain (4S) 4-hydroxyisophorone diastereomeric excess rate can reach 95%, yield can reach 96%; the cytochrome P450 BM3 Monooxygenase mutant catalyzes isophorone synthesis (4S) 4-hydroxyisophorone process is simple, environmental protection, and industrialization prospect is good.

The invention provides a computer-implemented method and system for non-invasive and step-by-step prediction of cancer risks and a storage medium. The method comprises the following steps: (1) determining a cancer signal score based on the level of a biomarker in a blood sample of a subject; (2) comparing the cancer signal score with a preset threshold value, and determining a primary screening positive subject; (3) further performing cancer risk determination and cancer species prediction by adopting an NGS method on the basis of the primarily screened positive subjects; wherein the biomarker is selected from at least one of AFP (Alpha Fetal Protein), CA125, CA15-3, CA19-9, CA72-4, CEA (Carcino Embryonic Acid), CYFRA (Cytochrome Factor Receptor Amplification) 21-1, ProGRP (Proso-Growth Radical Polymerase Chain Reaction), SCCA (Sequence

The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for modulating the activity of Cytochrome BD oxidase, or a mutant thereof. The disclosure also provides pharmaceutically acceptable compositions comprising compounds of the present disclosure and methods of using said compositions in the treatment of various diseases and disorders related to Cytochrome BD oxidase. Formula (I) and (II).

The present disclosure provides a P450 cytochrome enzyme for andrographolide synthesis and its application, belonging to the field of bioengineering. The present disclosure uses Saccharomyces cerevisiae CEN.PK2-1D as a host, and implements knockout of ROX1 and GAL80 genes on the genome, and integrative expression of GGPP synthase encoding gene and CPS diterpene synthase encoding gene at ROX1 site; and implements free expression of ApCPR and CYP71A8 and CYP71D10 both with truncated signal peptides, successfully constructing recombinant S. cerevisiae, and achieving de novo synthesis of 3,15,19-Trihydroxy-8(17),13-ent-labdadiene-16-oic acid. Compared with the blank, a response value of a product peak reaches 1.9*106, and this strategy provides necessary reference for analyzing biosynthetic pathway of andrographolide and using metabolic engineering to synthesize andrographolide and related derivatives thereof.

The invention discloses ganoderic acid mass production and application based on cytochrome P450 enzyme CYP512W6, the cytochrome P450 enzyme CYP512W6 in ganoderma lucidum is converted into a corresponding saccharomyces cerevisiae strain for heterologous expression, and three kinds of ganoderic acid, namely TLTOA, 3 beta-TLTOA and DLDOA, are obtained after fermentation. The invention provides a new implementation mode for heterologous biosynthesis of ganoderic acid in saccharomyces cerevisiae.

This invention relates to a cytochrome P450 oxidase STO1, its encoding gene, and its applications. This invention is the first to clone and identify a cytochrome P450 oxidase gene, STO1, from potato responsible for catalyzing the synthesis of spirogelothoraxone, and to determine the nucleotide sequence and translated amino acid sequence of this gene. This invention provides expression vectors, recombinant microorganisms, or transgenic cell lines containing this gene. This invention constructs an engineered Saccharomyces cerevisiae strain for producing spirogelothoraxone, in which the strong promoter ERG9 is replaced by the weak promoter HXT1 in the strain's genome, and the STO1, AtCPR, tHMG1, and STS genes are integrated. This invention also provides a method for constructing this engineered strain and a method for producing spirogelothoraxone using this engineered strain, which can be used for the preparation of spirogelothoraxone.

Provided are: a method for measuring one or more biomarkers to simply and accurately diagnose diseases associated with changes in the activities of cytochrome P450 metabolic enzymes (hereinafter referred to as "P450s"); and a method for detecting the one or more biomarkers. The methods focus on luminescence-based detection of the enzymatic activities of P450s, and involves reacting one or more P450s present in a sample collected in a low- or non-invasive manner, such as serum or urine, with a precursor of a luminescent / light-emitting substrate, metabolizing a luminescent substrate converted from the precursor to generate luminescence, and measuring the generated luminescence. Since many molecular species of P450s are known, the activities of different molecular species of P450s can be measured for each disease on the basis of luminescence intensity, and the activity pattern of each P450 can be analyzed to detect one or more biomarkers.

The present invention addresses the problem of providing a cytochrome P450 protein by identifying a gene of a Cupressaceae plant involved in the biosynthesis of ferruginol and encoding the cytochrome P450 protein with said gene. The present invention also addresses the problem of providing a new method for producing ferruginol on the basis of said gene.　Provided is a cytochrome P450 protein of an isolated CYP720 family or an active fragment thereof, the protein having an activity of oxidizing the carbon at position 12 of an abietane-type diterpene. The cytochrome P450 protein or an active fragment thereof is derived from a plant selected from the group consisting of Cupressaceae, Taxaceae, Cephalotaxaceae, Podocarpaceae, and Araucariaceae.

The present invention relates to mutant enzymes with enhanced properties and methods of using such enzymes to oxidize organic compound substrates. More specifically, provided herein are mutations in cytochrome P450 enzymes that enhance their peroxygenase activity and / or alter product selectivity as compared to wild-type cytochrome P450 enzymes. Also provided are uses of such mutant cytochrome P450 enzymes, e.g., for biocatalytic oxidation of carbon-hydrogen bonds by a peroxygenase pathway, or for oxidation of organic compound substrates.

This method provides in situ quantification of the overall mitochondrial redox state, the redox state of individual cytochromes such as complex III and IV, and methods for treatment should the redox state be identified as hyperoxidized. Mitochondrial rescue from IRI-mediated injury can be achieved using methylene blue, which acts as an alternate electron donor to bypass complex III.

The invention discloses a metabolic pathway of a clerodane type diterpenoid compound. The metabolic pathway is characterized in that related metabolic genes in the biosynthesis process of annonene, hardwickic acid, hatriwaic acid and divinatorin A are analyzed. The invention further discloses a preparation method of the clerodane type diterpenoid compound, and application of the clerodane type diterpenoid compound in the biosynthesis process of the clerodane type diterpenoid compound in the biosynthesis process of the clerodane type diterpenoid compound. The invention also verifies the function of some cytochrome P450 enzymes in the aspect of producing the clerodane diterpenoid compounds by utilizing the fermentation of yeast engineering bacteria, and lays a foundation for the industrialization of the clerodane diterpenoid compounds and intermediates of the clerodane diterpenoid compounds.

The invention provides a cytochrome P450 cholesterol side chain lyase mutant, recombinant saccharomyces cerevisiae for producing progesterone and application of the recombinant saccharomyces cerevisiae. The cytochrome P450 cholesterol side chain lyase mutant is obtained through ESM-2 language model screening, and the catalytic efficiency can be remarkably improved. The efficient recombinant saccharomyces cerevisiae is obtained by constructing the recombinant saccharomyces cerevisiae, optimizing the copy number of key enzymes, introducing an electron transfer system and overexpressing the key enzymes, the yield of progesterone is remarkably increased, and the recombinant saccharomyces cerevisiae is suitable for industrial production of progesterone and has important application value.

The present disclosure is directed to compositions comprising mitochondrial optogenetics-based gene therapies and their methods of use. In some embodiments, a composition described herein comprises an expression vector comprising a first nucleic acid sequence encoding a channelrhodopsin fusion protein and a second nucleic acid sequence encoding a luciferase protein. In some cases, the first nucleic acid sequence and the second nucleic acid sequence are operably linked to an expression control sequence. In some instances, the channelrhodopsin fusion protein comprises a channelrhodopsin protein linked to an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS). In some implementations, when the expression vector is expressed, the luciferase protein is localized to the cytosol. In some cases, the IMM-MLS comprises a leading sequence from a mitochondrial inner membrane protein selected from ABCB10, ABCB140, Cytochrome C, and renal outer medullary potassium channel (ROMK).

The present invention relates to compounds of formula (I) wherein A is a 3-10 membered carbocyclic ring or a 4-12 membered heterocyclic ring containing 1-4 heteroatoms selected from O, N or S; B is any one of the following groups (1), (2) or (3); C is any one of the following groups (1'), (2'), (3') or (4'); G1 is CH2, NH or O; G2 and G3 are independently of each other CH or N; Z is -C(O)-, -SO2-, -C 1‑3 alkyl- or -CH2-C(O)-; L is a bond, -C 1‑7 alkyl- or -C 1‑7 alkenyl-. The compounds of formula (I) are inhibitors of cytochrome P450 monooxygenase 11A1 (CYP11A1). The compounds are useful as medicaments for the treatment of steroid receptor, e.g. androgen receptor or estrogen receptor dependent diseases and disorders such as cancer including prostate cancer and estrogen cancer.

The present disclosure relates to relates to compounds that inhibit CYP3A4 selectively, pharmaceutical compositions, and methods of using the compounds and composition for treating a disease or disorder with a drug that is a P450 enzyme substrate. In addition, the disclosed compounds and compositions can be used for preventing P450 enzyme metabolism of a drug. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention relates to compounds of Formula (I), as well as prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of preparation thereof. The compounds disclosed herein are useful in the treatment of diseases in which the expression of P-glycoprotein and / or cytochrome P450 (e.g., CYP3A4) is modulated (e.g., cancers that have developed multi-drug resistance).

The application discloses a cytochrome P450BM3 mutant, a carrier, microorganisms and application thereof, and belongs to the technical field of chemical enzyme synthesis.The application discloses a synthetic route of a key drug intermediate dehydro-nandrolone acetate synthesized by a chemical enzyme method, wherein enzyme catalysis and chemical catalysis are included.The enzyme catalysis includes a cytochrome P450 mutant and 17beta-steroid reductase, and a one-pot two-step method is used to catalyze acid to be removed to generate 7beta-hydroxynandrolone.Combined with chemical catalysis, the 7beta-hydroxynandrolone is subjected to dehydration esterification to generate the dehydro-nandrolone acetate.The synthetic route has short steps, high yield and the ability to reduce the production cost of related steroid drugs.

The present application provides a kind of cytochrome P450 monooxygenase gene and the protein coded by it, recombinant plasmid and application derived from ramie, the coding region sequence of the cytochrome P450 monooxygenase gene derived from ramie is as shown in SEQ ID NO:1, the amino acid sequence of the protein coded by it is as shown in SEQ ID NO:2.The present application takes ramie as research object, obtains ramie cytochrome P450 monooxygenase gene (BnMAX1) by three generations sequencing and gene annotation comparison.Longer coding sequence of the target gene is obtained by PacBio Sequel sequencing, which is simple, fast and easy to operate.The function of the gene is verified by cloning identification, bioinformatics, expression pattern and genetic transformation analysis, which shows that the gene has the effect of relieving plant cadmium toxicity.The acquisition and application of the gene provide basic theoretical support for molecular improvement of cadmium tolerance of ramie, and provide new technical means for how to improve the ecological restoration ability of ramie under heavy metal cadmium stress.

This invention relates to the field of pest control technology, and discloses a double-stranded RNA and its application in the control of citrus aphids. The double-stranded RNA comprises a double-stranded RNA consisting of the nucleotide sequence shown in SEQ ID NO:2 and its reverse complementary nucleotide sequence; the nucleic acid molecule encoding the double-stranded RNA is shown in SEQ ID NO:1 or SEQ ID NO:3. The double-stranded RNA provided by this invention can simultaneously target the chitin synthase gene, cytochrome P450 monooxygenase gene, and epidermal protein gene of the brown citrus aphid, and simultaneously silence the expression of these three key genes through an RNA interference mechanism, leading to inhibited growth and development or death of the brown citrus aphid. Therefore, the double-stranded RNA provided by this invention can efficiently and specifically control the brown citrus aphid; it can reduce the use of chemical pesticides, is green and environmentally friendly, and safe and harmless.

The present application relates to the technical field of biosynthesis, and specifically discloses a method for selectively hydroxylating 16-position of dehydroabietyl acid based on CYP153 family cytochrome P450 enzyme, which comprises the following steps: plasmid construction, heterologous expression of CYP153A99-RhFRED in Escherichia coli, heterologous expression of opt13 in Escherichia coli, and crude enzyme catalytic conversion reaction. By optimizing the codon bias of the protein sequence of cytochrome monooxygenase in the CYP153 family, the p450 enzyme CYP153A99 with the biological catalytic function of catalyzing the hydroxylation of C16 position of dehydroabietyl acid is obtained, high-site selective oxidation of dehydroabietyl acid is realized, the substrate spectrum and application field of the CYP153 family P450 enzyme are expanded, and a new technical path is provided for the green synthesis of dehydroabietyl acid derivatives.

Described herein are steroid or steroid-like compounds including at least one isonitrile group and which inhibit the activity of a cytochrome P450 enzyme, as well as compositions including the compounds. Also included are methods of inhibiting activity of a cytochrome P450 in a subject having a steroid-responsive cancer, a Mycobacterium tuberculosis infection, a fungal infection, or a trypanosome infection, the method comprising administering to the subject the compound including at least one isonitrile group or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit the CYP activity in the subject.

The invention belongs to the technical field of biological enzymes, and discloses a cytochrome P450 enzyme mutant and application thereof, the mutant is subjected to any one of the following amino acid mutations on an amino acid sequence as shown in SEQ ID NO.2: L294A, L294G, L294A + T89H and L294G + T89H. The cytochrome P450 enzyme mutant provided by the invention can selectively catalyze a 7beta hydroxylation reaction of a steroid compound to generate a corresponding 7beta-hydroxylated steroid compound (such as UDCA, CA and the like), and has excellent selectivity (-96%) and / or relatively high yield (-70%), the catalytic reaction efficiency is high, and the reaction time can be shortened to be within 20 hours.

The present invention provides cytochrome bd oxidase inhibitors. The present invention provides the use of the cytochrome bd oxidase inhibitors as a medicament to treat a bacterial infection. The present invention also provides the use of the cytochrome bd oxidase inhibitors as a medicament to treat a bacterial infection with a QcrB inhibitor.

The present disclosure relates to relates to compounds that inhibit CYP3A4 selectively, pharmaceutical compositions, and methods of using the compounds and composition for treating a disease or disorder with a drug that is a P450 enzyme substrate. In addition, the disclosed compounds and compositions can be used for preventing P450 enzyme metabolism of a drug. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention discloses application of fungal cytochrome P450 enzyme, and belongs to the technical field of biological enzyme catalysis. The fungal cytochrome P450 enzyme is derived from Gibberella fujikuroi, and the amino acid of the fungal cytochrome P450 enzyme is as shown in SEQ ID NO. 1 or has at least 80% similarity with the sequence as shown in SEQ ID NO. 1; the fungal cytochrome P450 enzyme at least can catalyze 7beta hydroxylation of five steroids L1, L2, L3, L4 and L5, and has excellent selectivity and high yield, and corresponding hydroxylation products can directly or indirectly generate ursodesoxycholic acid. The invention provides a good prospect for synthesizing ursodesoxycholic acid more environmentally and efficiently by using a biological enzyme method.

This invention discloses a herbicide-resistant cytochrome P450 gene, BjCYP71C2, its protein, plasmid, and their applications, belonging to the field of plant genetic engineering technology. The nucleotide sequence of this gene is SEQ ID NO:1 or has at least 80% identity with SEQ ID NO:1. This invention also discloses the protein polypeptide and plasmid encoded by the above gene. The purpose of this gene is to express it transgenic in plants, cultivating herbicide-resistant plants for selective weed control using herbicides.